Glioblastoma (GBM) Clinical Trials

30 recruitingLast updated: June 18, 2026

There are 30 actively recruiting glioblastoma (gbm) clinical trials across 15 countries. Studies span Not Applicable, Phase 2, Phase 1, Early Phase 1, Phase 3. Top locations include Beijing, Beijing Municipality, China, Phoenix, Arizona, United States, Jacksonville, Florida, United States. Updated daily from ClinicalTrials.gov.


Glioblastoma (GBM) Trials at a Glance

30 actively recruiting trials for glioblastoma (gbm) are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Not Applicable with 10 trials, with the heaviest enrollment activity in Beijing, Phoenix, and Jacksonville. Lead sponsors running glioblastoma (gbm) studies include Nader Sanai, Peking University Third Hospital, and Second Affiliated Hospital, School of Medicine, Zhejiang University.

Browse glioblastoma (gbm) trials by phase

Treatments under study

About Glioblastoma (GBM) Clinical Trials

Looking for clinical trials for Glioblastoma (GBM)? There are currently 30 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioblastoma (GBM) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioblastoma (GBM) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting
Not Applicable

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Glioblastoma (GBM)IDH Wildtype Glioblastoma
Ottawa Hospital Research Institute50 enrolled2 locationsNCT06850766
Recruiting
Early Phase 1

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeGlioblastoma (GBM)Recurrent Glioblastoma+1 more
Beijing Tiantan Hospital5 enrolled2 locationsNCT07648823
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled13 locationsNCT07326566
Recruiting
Phase 1Phase 2

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Not Applicable

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

Glioblastoma (GBM)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35 enrolled1 locationNCT07375992
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Not Applicable

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN

Glioblastoma (GBM)
Medical University of Vienna30 enrolled1 locationNCT07627334
Recruiting
Not Applicable

LITT for Ultra-early GBM Recurrence

Glioblastoma (GBM)Glioblastoma - Category
Insel Gruppe AG, University Hospital Bern12 enrolled1 locationNCT07616986
Recruiting

Mental Health and Suicidality in Glioblastoma Patients in Germany

Glioblastoma (GBM)
University Hospital, Essen176 enrolled6 locationsNCT07409584
Recruiting
Early Phase 1

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

Glioblastoma (GBM)
Nader Sanai78 enrolled1 locationNCT07485049
Recruiting
Phase 1

Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma

Glioblastoma (GBM)
University of Virginia12 enrolled1 locationNCT07343986
Recruiting
Phase 2

G-CSF After Chemo-radiation in Patients With Glioblastoma

Glioblastoma (GBM)MGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme
Massachusetts General Hospital60 enrolled1 locationNCT06649851
Recruiting
Phase 2

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Glioblastoma (GBM)
Diakonos Oncology Corporation180 enrolled16 locationsNCT06805305
Recruiting
Not Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

Brain MetastasisGlioblastoma Multiforme (GBM)Glioblastoma (GBM)+2 more
Peking University Third Hospital27 enrolled4 locationsNCT07552233
Recruiting
Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

GlioblastomaNeoplastic DiseaseGlioblastoma (GBM)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited50 enrolled4 locationsNCT07100730
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

Glioblastoma (GBM)
Myosin Therapeutics Inc.36 enrolled3 locationsNCT07185880
Recruiting
Phase 2

Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma

Glioblastoma (GBM)
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT07511725
Recruiting
Not Applicable

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)

GlioblastomaGlioblastoma (GBM)High-Grade Glioma (WHO III-IV)
Medical University of Warsaw35 enrolled2 locationsNCT07488754
Recruiting
Not Applicable

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

Glioblastoma (GBM)Astrocytoma, Grade IV
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07459101
Recruiting
Early Phase 1

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Brain MetastasasesGlioblastoma (GBM)
Nader Sanai15 enrolled1 locationNCT07268053